Efficient distribution, new partnerships
and a broad range of high-margin products
to be launched in major consumer markets
NYSE: ACB
TSX:ACB
EDMONTON, June 21, 2019 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB), the Canadian
company defining the future of cannabis worldwide, today announced
its plans for the highly-anticipated expansion of the consumer
cannabis market into vapes, concentrates, and edibles. The Company
is also preparing to launch a national public awareness campaign
this fall, educating consumers, provinces and retailers about the
safe usage and consumption of these new derivative products.
Through a combination of new and enhanced facilities, Aurora
intends to produce new, high-quality products across the country in
a variety of product categories. Aurora recently entered into a
supply agreement with PAX Labs Inc., a leading consumer technology
brand in cannabis. With the PAX partnership, the Company will have
the market leading PAX Era device to compete in the Closed Loop
category and will also launch a new range of vape products, at
various price points, targeted to all major consumer markets
through both 510 thread cartridges and disposable single-use
units.
"Aurora is the world's leading producer of high-quality cannabis
and we're ready to introduce high-value product additions to this
improved, federally legal market," said the Company's CEO
Terry Booth. "From the beginning,
we've invested in industry-leading production and distribution
technology, and in consumer research to drive products to market
that consumers will desire. These things, together with the dynamic
partnerships we've entered into on the accessory and technology
fronts, position us well for this new market launch in December as
per Health Canada's recent regulatory amendments."
On the issue of product education and awareness, Booth said: "We
will show leadership when it comes to educating consumers on the
safe, responsible consumption of cannabis edibles. Over the next
few months we will be rolling out educational campaigns across
Canada to help provide consumers
with the information they need to make safe and sound
decisions."
To support the successful launch of vapes, concentrates, and
edibles products, and to continue to ensure sufficient supply for
domestic and international markets, Aurora has established
production hubs in Western Canada,
on the same federal property as Aurora Sky at the Edmonton International Airport, and in
Eastern Canada at Aurora River, in
Bradford, Ontario and at Aurora
Vie in Pointe-Claire, Quebec near
Montréal. These centres will provide centralized production,
packaging, logistics and distribution capabilities. In total, they
comprise more than 450,000 square feet and are strategically
located to efficiently distribute our products to markets across
the country.
Aurora Air, a 20,000 square foot manufacturing facility, is now
in the final stages of receiving its Health Canada license. Located
near the Edmonton International
Airport and Aurora Sky, Air will be home to several of the new
production lines for edible products. New industrial extraction
systems have also been installed at Aurora Sky and Aurora
River.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 24 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern
Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia,
HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs,
Whistler, and Chemi Pharmaceutical – Aurora is distinguished by its
reputation as a partner and employer of choice in the global
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals
(OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI),
EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty
Group (private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur, and include, but are not limited to, the
completion of the launch of the vape and edibles products, the
successful launch of the public education campaign, and
the completion of licensing for the Air facility. These statements
are only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release, including,
but not limited to consumer demand for the new products.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.